Thrilled to share that Brown University and OncoOne have published key aspects of oxMIF biology in Redox Biology. Our most recent paper, “Redox-dependent plasticity of oxMIF facilitates its interaction with CD74 and therapeutic antibodies,” explores how MIF, undergoes oxidation to oxMIF by neutrophil-released myeloperoxidase (MPO).

Thrilled to share a significant milestone: Our groundbreaking research paper on pretargeted radioimmunotherapy using the novel PreTarg-it® antibody ON105, titled “Pretargeted radioimmunotherapy with the novel anti-oxMIF/HSG bispecific antibody ON105 results in significant tumor regression in murine models of cancer,” is now published in the AACR

Our thanks to Genetic Engineering & Biotechnology News for featuring OncoOne’s CEO and Co-founder, Randolf Kerschbaumer, in an article highlighting the potential of multispecific antibody technologies, including our PreTargit® platform. Visit the link below to read the article and discover how we are developing our

Check out the recent article from Labiotech.eu that lists OncoOne as one of the 8 biotech companies to know in Austria! We are thrilled to be mentioned alongside other exciting companies and to be recognized for our work in generating novel immunotherapies, such as our

Our team at OncoOne is developing a pipeline of therapeutic antibodies capable of targeting Hashtag#oxMIF, the disease-related isoform of MIF discovered by our founders. Our mission is to leverage our breakthrough discovery and oxMIF’s potential as a target for systemic treatment of rheumatoid arthritis, nephritis,